TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04721600

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Evoke Radiofrequency Device
Description: Enrolled subjects will undergo up to 3 successive bi-weekly (every 2 weeks) treatments.Treatment area will include face and under chin
Study: NCT01928732

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Processing Therapy (CPT)
Description: CPT consists of cognitive therapy and a written trauma narrative. Patients are taught to challenge their beliefs through Socratic questioning and the use of daily worksheets. The initial focus is on beliefs such as denial and self-blame, and then shifts to overgeneralized beliefs about self and the world. Patients process their trauma directly by writing a narrative of their traumatic event(s) that they read to themselves and to therapists. The typical protocol consists of 12 1-hr sessions. In this study, the 12-session protocol will be followed, but participants who improve more rapidly may finish in 10 sessions and those who improve more slowly may receive up to 2 additional sessions to continue working on stuck points with challenging beliefs worksheets.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Prolonged Exposure (PE)
Description: PE is a manualized, 90-minute, 8-15 week treatment program based on emotional processing theory, which posits that anxiety disorders, including PTSD, reflect pathological fear structures in which emotional and cognitive associations among different elements do not accurately represent reality and renders the individual dysfunctional and distressed. PE is designed to correct erroneous connections in the targeted memory structure. PTSD sufferers typically experience two key pathological emotional response sets and related cognitions: The world is an utterly dangerous place, and I am completely incompetent and unable to cope with stress. In this study, the 12-session protocol will be followed, but participants improve more rapidly may finish in 10 sessions and those who improve more slowly may have up to 2 additional sessions to continue working on exposure.
Study: NCT03252210

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Preoperative Stereoscopic Localization
Description: 1.Confirm the nodule's location and measure the distance between the nodule and anatomic landmarks from the CT scan. 2.According to the results of the first step，confirm the needle puncture site of the chest wall. 3.After general anesthesia and Patient positioning are completed, the needle is then inserted via the needle puncture site .
Study: NCT01008917

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib with temsirolimus
Description: Weekly intravenous temsirolimus with daily oral sorafenib
Study: NCT01682928

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV/Oral Hydration and Bedrest
Description: * Maternal BP (sitting)~* Pulse Pressure~* Pulse~* Urine Specific Gravity BID~* Fetal Heart Rate~* Maternal Body Weight US Procedures~* AC/EFW~* Umbilical Artery Doppler Flow (Baseline, day 3, 7 {or Discharge})~* Uterine Artery Doppler Flow (Baseline, day 3, 7 {or Discharge})~* AFI (Baseline, day 3, 7 {or Discharge})~ALL ITEMS ABOVE MUST BE COMPLETED BEFORE:~* 1 Liter Water PO over 2 hours~* 1 Liter IV Fluid Bolus (NS) then titrated to 75 ml\\hr for duration of the study participation~* Strict I/O's~* Vital signs

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hydrotherapy
Description: * Maternal BP (sitting)~* Pulse Pressure~* Pulse~* Urine Specific Gravity BID~* Fetal Heart Rate~* Maternal Body Weight US Procedures~* AC/EFW~* Umbilical Artery Doppler Flow (Baseline, day 3, 7 {or Discharge})~  o 1 hour +/- 30 minutes after submersion therapy~* Uterine Artery Doppler Flow (Baseline, day 3, 7 {or Discharge})~  o 1 hour +/- 30 minutes after submersion therapy~* AFI (Baseline, day 3, 7 {or Discharge}) o 1 hour +/- 30 minutes after submersion therapy~ALL ITEMS ABOVE MUST BE COMPLETED BEFORE:~* 1 Liter Water PO over 2 hours~* 1 Liter IV Fluid Bolus (NS) then titrated to 75 ml\\hr for duration of the study participation~* Strict I/O's~* Vital signs~* HYDROTHERAPY TWICE DAILY FOR 3-7 DAYS o Blood pressure, pulse, pulse pressure, body weight, and fetal heart rate before and after submersion therapy
Study: NCT01209156

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F] PBR111
Description: Subjects will be injected with 5mCi (not to exceed a maximum of 5.5 mCi) of \[18F\]PBR111, followed by PET imaging.
Study: NCT02151084

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selumetinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selumetinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Study: NCT01197924

Intervention type: OTHER
Intervention: IRMf Bold
Description: IRMf BOLD of the working memory

Intervention type: OTHER
Intervention: IRMf Bold
Description: IRMf BOLD of the working memory
Study: NCT03424122

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Bendamustine administered intravenously on Days 1 and 2 of each cycle for up to 6 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Ibrutinib administered orally once daily.
Study: NCT04268745

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Balance training
Description: Progressive balance training within virtual environments

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Vestibular Rehabilitation
Description: Progressive balance training and gaze stability exercises
Study: NCT04855383

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: The effect of intramuscular injection of triple doses of human chorionic gonadotropin in frozen embryo transfer cycles
Description: Patients receive 5,000 IU of human chorionic gonadotropin by intramuscular injection, 72 hours before embryo transfer, on the day of embryo transfer, and 72 hours after embryo transfer.
Study: NCT00988364

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simvastatin
Description: Simvastatin 20mg daily for 3 months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vytorin
Description: Vytorin 20/10mg daily for 3 months.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo one tablet daily times 3 months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ezetimibe
Description: Ezetimibe 10mg daily for 3 months.
Study: NCT03137693

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Breast-conserving Surgery
Description: Breast-conserving surgery will be scheduled for 6-8 weeks after SABR and will be conducted by a Moffitt breast surgeon.
Study: NCT03263767

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 30 mg/m² Intravenous 5 days from Day-6 to Day-2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 30 mg/m² Intravenous 5 days from Day-6 to Day-2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clofarabine
Description: 30 mg/m² Intravenous 5 days from Day-6 to Day-2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clofarabine
Description: 30 mg/m² Intravenous 5 days from Day-6 to Day-2

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Full body irradiation
Description: 2 grays at Day-1

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Full body irradiation
Description: 2 grays at Day-1

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Full body irradiation
Description: 2 grays at Day-1

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Full body irradiation
Description: 2 grays at Day-1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 14 mg/kg intravenous 2 days at Day - 6 and day -5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 14 mg/kg intravenous 2 days at Day - 6 and day -5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 14 mg/kg intravenous 2 days at Day - 6 and day -5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 14 mg/kg intravenous 2 days at Day - 6 and day -5
Study: NCT02192918

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Airbrush
Description: The American Academy of Dermatology Sun Smart pamphlet will be given at the baseline session. It has brief tips for reducing skin cancer risk, but does not mention sunless tanning or relaxation activities. Participants in the airbrush condition will receive 4 airbrush tan sessions, once every two weeks, over the course of 2 months.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Airbrush Plus
Description: The American Academy of Dermatology Sun Smart pamphlet will be given at the baseline session. It has brief tips for reducing skin cancer risk, but does not mention sunless tanning or relaxation activities. Participants will complete 4 airbrush tan sessions, once every two weeks, over the course of 2 months. Additionally, they may choose 8 sessions, 1 per week, of the following activities at no cost: massage, pedicure, yoga class, or dance class.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Delayed Airbrush
Description: The American Academy of Dermatology Sun Smart pamphlet will be given at the baseline session. It has brief tips for reducing skin cancer risk, but does not mention sunless tanning or relaxation activities. Participants will receive access to one of each of the following after the 6-month assessment at no cost: airbrush tan, massage, pedicure, yoga class, and dance class
Study: NCT03344042

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: 100mcg Fentanyl
Study: NCT03263767

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 50 mg/kg intravenous 2 days at day +3 and day +4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 50 mg/kg intravenous 2 days at day +3 and day +4
Study: NCT00218972

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic interval training

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: moderate intensity training

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Recommendation of regular exercise
Study: NCT03235089

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Test Lens
Description: Daily disposable contact lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Test Lens
Description: Daily disposable contact lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Control Lens
Description: Focus Dailies All Day Comfort contact lens (nelfilcon A)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Control Lens
Description: Focus Dailies All Day Comfort contact lens (nelfilcon A)
Study: NCT01595555

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stress Free Now
Description: 8 week mindfulness online program with the following content: 8 Weekly lesson of the week (audio), 8 Weekly mindfulness practice (audio), Daily articles on concepts and information about stress, relaxation and mindfulness, Daily motivational quotes and tips, Biweekly email reminder to participate in the program.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stress Free Now
Description: 8 week mindfulness online program with the following content: 8 Weekly lesson of the week (audio), 8 Weekly mindfulness practice (audio), Daily articles on concepts and information about stress, relaxation and mindfulness, Daily motivational quotes and tips, Biweekly email reminder to participate in the program.
Study: NCT01363115

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Orange Juice fortified with Calcium and Vitamin D
Description: Three 240 mL glasses of orange juice fortified with 350 mg Ca and 100 IU of D per serving

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Orange juice without Ca or VitD
Description: Three 240 mL glasses of orange juice without Ca or VitD

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutritional Counseling
Description: Individual and group nutritional counseling by a registered dietitian

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nutritional Counseling
Description: Individual and group nutritional counseling by a registered dietitian
Study: NCT03969017

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegylated interferon (Peg IFN)α-2b
Description: Participants in NAs+Peg IFN Group will be treated by Peg IFNα-2b （180ug per week, the dose will be changed to 135ug or 90ug per week during the treatment if patients could not tolerate the side effects of Peg IFNα-2b). Peg IFNα-2b treatment will be performed until HBsAg \<0.05IU/ml, with a maximum duration of 48 weeks.

Intervention type: DRUG
Group type: OTHER
Intervention: Nucleoside （acid）analogue (NAs)
Description: Both of NAs Group and NAs+Peg IFN Group will be treated with NAs as before enrollment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nucleoside （acid）analogue (NAs)
Description: Both of NAs Group and NAs+Peg IFN Group will be treated with NAs as before enrollment.
Study: NCT00751855

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Prolonged Exposure therapy
Description: 10 weekly sessions

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Prolonged Exposure therapy
Description: 10 weekly sessions

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrocortisone
Description: 30mg 45 minutes prior to each PE session including imaginal exposure (8 total)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study: NCT03238924

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: 40 IU oxytocin nasal spray, self-administered
Study: NCT00853099

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT00869076

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacist Management
Description: Pharmacist Managed the patient's diabetes in collaboration with their primary care physician

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Patient was managed by their primary care physician as usual
Study: NCT03238924

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Saline nasal spray, self-administered
Study: NCT03555682

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 2-HOBA
Description: 2-HOBA is a compound found in buckwheat and is given as 2-HOBA acetate

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 2-HOBA
Description: 2-HOBA is a compound found in buckwheat and is given as 2-HOBA acetate
Study: NCT01000948

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZD4054
Description: ZD4054 10 mg given orally, once daily in tablet form to all patients in two years or until investigator consider the drug for useless.
Study: NCT03555682

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Comparator
Study: NCT02561221

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle Counseling
Description: Trained health coaches delivered the active intervention - a comprehensive, high-intensity program, as recommended first-line therapy by the 2013 American Heart Association/American College of Cardiology/The Obesity Society Guidelines.
Study: NCT03675984

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: asymmetrical stabilization exercise
Description: Exercise is combined to form an appropriate combination of motion (Side-lying, Bird-dog, Prone arm lift, Prone leg lift) according to the curve pattern and muscle weakness of each patient's.
Study: NCT00345631

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Manual Compression
Description: Manual compression

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vascular Closure Device
Description: Investigational vascular closure device
Study: NCT01029041

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strengthening Exercises
Description: Exercises that aim the improvement of muscular strength of arms and legs

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stretching exercises
Description: Exercises that aim the improvement of muscular flexibility of arms, legs and spine
Study: NCT03051919

Intervention type: OTHER
Intervention: observation

Intervention type: OTHER
Intervention: observation

Intervention type: OTHER
Intervention: observation

Intervention type: OTHER
Intervention: observation
Study: NCT01252979

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Medium-Chain Triglycerides
Description: Subjects will take supplemental MCT oil 3 times a day for 6 months
Study: NCT04256252

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: A scheduled therapeutic regimen with low-dose rituximab was performed.
Study: NCT03263767

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 50 mg/kg intravenous 2 days at day +3 and day +4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 50 mg/kg intravenous 2 days at day +3 and day +4

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: stem cell transplantation
Description: at D0 intraveinous Depending on donor : the stem cells will be extracted from blood (CD34+) or from bone marrow (CD34+ and nuclear cells)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: stem cell transplantation
Description: at D0 intraveinous Depending on donor : the stem cells will be extracted from blood (CD34+) or from bone marrow (CD34+ and nuclear cells)
Study: NCT01700010

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapatinib and Paclitaxel
Description: Lapatinib comes in tablet form and is taken by mouth at a dose of 1,000 mg every day. Paclitaxel will be given through the vein (IV) at a dose of 80 mg/m2 on days 1, 8, and 15 at each 28 day cycle. If cancer does not progress and study treatment can be tolerated after 6 cycles of paclitaxel and lapatinib, paclitaxel will be stopped and lapatinib will continue until disease progression, side effects cannot be tolerated, participant is removed from or withdraws from study, or for other reasons.~Subjects with locally advanced disease who respond to treatment and are felt to be appropriate for local therapy may proceed to receive local therapy as deemed appropriate by the managing physician after a minimum of 6 cycles or upon achieving complete remission followed by an additional 2 cycles. Subjects who proceed to receive local therapy will be removed from protocol therapy. Subjects who elect not to receive or are not candidates for local therapy may continue treatment on protocol.
Study: NCT03052023

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: dual approach laparoscopic inguinal hernioplasty
Description: after pneumoperitoneum is done preperitoneal pneumo-dissection is done and then peritoneal incision done . dissection preperitoneally and sac dissection will be easy approached

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TAPP
Description: pneumoperitoneum is done and then through abdominal approach peritoneal dissection in done and sac reduction and then mesh fixation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: (lichtenstein) repair
Description: inguinal incision is done and inguinal canal approach anteriorly and then sac dissection and excision then mesh fixation to posterior wall and closure the incision in layers
Study: NCT03691363

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: M-STEP
Description: Youth will be assessed using actigraphy at baseline, and will then be asked to exercise for 1) a duration of 10 minutes \> MVPA at baseline with 2) HR\>120 while being monitored by a Fitbit. Youth will be asked to exercise daily, and intensity and duration will be increased every few days for a goal of 60 minutes per day at a HR\>140 (low end of MVPA). The intervention will be 6 weeks in duration.
Study: NCT02146027

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fermented Milk Drink Yakult 40
Description: Lactobacillus casei Shirota, with 40 billion bacteria per 80 g (concentration of 5 x 10\^8 CFU/g). Intervention will be used for 12 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Fermented Milk Drink Yakult 40
Description: Lactobacillus casei Shirota, with 40 billion bacteria per 80 g (concentration of 5 x 10\^8 CFU/g). Intervention will be used for 12 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fermented Milk Drink Yakult 40
Description: Ingredients: Skimmed milk and/or Reconstituted Skimmed Milk, Sugar, Glucose, Live Lactic Bacteria (Lactobacillus casei Shirota) 40 billions per 80 g - concentration of 5 x 108 CFU/g), Flavour. Gluten Free.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Fermented Milk Drink Yakult 40
Description: Ingredients: Skimmed milk and/or Reconstituted Skimmed Milk, Sugar, Glucose, Live Lactic Bacteria (Lactobacillus casei Shirota) 40 billions per 80 g - concentration of 5 x 108 CFU/g), Flavour. Gluten Free.
Study: NCT04161001

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine/Olmesartan 10/40mg (Combination drug), Ezetimibe/Rosuvastatin 10/20mg(Combination drug)
Description: co-administration of Sevikar tab. 10/40mg(Amlodipine/Olmesartan 10/40mg), Rosuzet Tab. 10/20mg(Ezetimibe/Rosuvastatin 10/20mg) and placebo of Olmetec Tab. 40mg(Olmesartan 40mg)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Olmesartan 40mg, Ezetimibe/Rosuvastatin 10/20mg(Combination drug)
Description: co-administration of Olmetec tab. 40mg(Olmesartan 40mg), Rosuzet Tab. 10/20mg(Ezetimibe/Rosuvastatin 10/20mg) and placebo of Sevikar tab. 10/40mg (Amlodipine/Olmesartan 10/40mg)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Amlodipine/Olmesartan 10/40mg (Combination drug)
Description: co-administration of Sevikar tab. 10/40mg(Amlodipine/Olmesartan 10/40mg, and placebo of Rosuzet Tab. 10/20mg(Ezetimibe/Rosuvastatin 10/20mg), Olmetec Tab. 40mg(Olmesartan 40mg)
Study: NCT03908970

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1% OPA-15406
Description: Twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Twice daily